文献速递冠心病心力衰竭与心肌病

恩格列净在急性心肌梗死中的应用:EMMY试验

Empagliflozin in acute myocardial infarction: the EMMY trial.
PubMed 文献 · Eur Heart J · 2022-01-01

EMMY试验为多中心双盲随机对照研究,纳入476例急性心肌梗死且肌酸激酶>800 IU/L的患者,在PCI后72小时内给予恩格列净10 mg每日一次或安慰剂。主要终点26周NT-proBNP变化在恩格列净组显著更优,降幅达15%(95%CI -4.4%至-23.6%,P=0.026),同时多项超声心动图参数显著改善。

要点

  • 急性心肌梗死后早期使用恩格列净可显著降低26周NT-proBNP水平。
  • 恩格列净组左室射血分数改善更显著,左室收缩及舒张末期容积更小。
  • 恩格列净组心衰住院7例中占3例,其他预设严重不良事件罕见且组间无显著差异。

核心结论

  • 在近期急性心肌梗死患者中,恩格列净与26周NT-proBNP显著更大程度降低相关,并伴随超声心动图功能与结构参数的显著改善。

研究设计与样本

  • 学术性、多中心、双盲随机对照试验,纳入476例急性心肌梗死伴肌酸激酶升高(>800 IU/L)的患者。
  • 患者于经皮冠状动脉介入治疗后72小时内随机接受恩格列净10 mg每日一次或匹配安慰剂。
  • 主要终点为26周NT-proBNP变化;次要终点包括超声心动图参数变化。

主要发现

  • 基线NT-proBNP中位数(四分位距)为1294(757-2246)pg/mL。
  • 校正基线NT-proBNP、性别和糖尿病状态后,恩格列净组NT-proBNP降幅较安慰剂组显著更大,低15%(95%CI -4.4%至-23.6%,P=0.026)。
  • 左室射血分数绝对改善更显著(1.5%,95%CI 0.2-2.9%,P=0.029)。
  • 平均E/e'降幅更大,为6.8%(95%CI 1.3-11.3%,P=0.015)。
  • 左室收缩末期和舒张末期容积分别低7.5 mL(95%CI 3.4-11.5 mL,P=0.0003)和9.7 mL(95%CI 3.7-15.7 mL,P=0.0015)。

临床怎么用

  • 对于急性心肌梗死后早期(PCI后72小时内)且肌酸激酶显著升高的患者,可考虑启动恩格列净10 mg每日一次以改善NT-proBNP及超声心动图参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Sodium-glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and for death in patients with symptomatic heart failure. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. METHODS AND RESULTS: In this academic, multicentre, double-blind trial, patients (n = 476) with acute myocardial infarction accompanied by a large creatine kinase elevation (>800 IU/L) were randomly assigned to empagliflozin 10 mg or matching placebo once daily within 72 h of percutaneous coronary intervention. The primary outcome was the N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks. Secondary outcomes included changes in echocardiographic parameters. Baseline median (interquartile range) NT-proBNP was 1294 (757-2246) pg/mL. NT-proBNP reduction was significantly greater in the empagliflozin group, compared with placebo, being 15% lower [95% confidence interval (CI) -4.4% to -23.6%] after adjusting for baseline NT-proBNP, sex, and diabetes status (P = 0.026). Absolute left-ventricular ejection fraction improvement was significantly greater (1.5%, 95% CI 0.2-2.9%, P = 0.029), mean E/e' reduction was 6.8% (95% CI 1.3-11.3%, P = 0.015) greater, and left-ventricular end-systolic and end-diastolic volumes were lower by 7.5 mL (95% CI 3.4-11.5 mL, P = 0.0003) and 9.7 mL (95% CI 3.7-15.7 mL, P = 0.0015), respectively, in the empagliflozin group, compared with placebo. Seven patients were hospitalized for heart failure (three in the empagliflozin group). Other predefined serious adverse events were rare and did not differ significantly between groups. CONCLUSION: In patients with a recent myocardial infarction, empagliflozin was associated with a significantly greater NT-proBNP reduction over 26 weeks, accompanied by a significant improvement in echocardiographic functional and structural parameters. CLINICALTRIALS.GOV REGISTRATION: NCT03087773.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. von Lewinski, Kolesnik, Tripolt, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022. PMID: 36036746. doi:10.1093/eurheartj/ehac494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。